Sutro Biopharma (STRO) PE Ratio: History & Chart

Sutro Biopharma, Inc.(STRO)

Biotechnology · South San Francisco, CA

$14.45-0.68 (-4.49%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Sutro Biopharma, Inc.

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.

South San Francisco, CA

128 employees

www.sutrobio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jane Chung

View full financials

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Sutro Biopharma, Inc. (STRO)	$139.84M	N/A	N/A	N/A	N/A
Alpha Cognition Inc (ACOG)vs ›	$139.47M	N/A	N/A	N/A	N/A
Immuneering Corporation (IMRX)vs ›	$139.04M	N/A	N/A	N/A	N/A
KORU Medical Systems, Inc. (KRMD)vs ›	$137.80M	N/A	1879.79	1257.96	875.52
Atrium Therapeutics, Inc. (RNA)vs ›	$136.67M	N/A	N/A	N/A	N/A
Nyxoah S.A. (NYXH)vs ›	$143.10M	N/A	N/A	N/A	N/A
Organigram Global Inc. (OGI)vs ›	$136.57M	2.18	9.74	18.49	18.49
Protara Therapeutics, Inc. (TARA)vs ›	$143.60M	N/A	N/A	N/A	N/A
NervGen Pharma Corp. Common stock (NGEN)vs ›	$143.84M	N/A	N/A	N/A	N/A
Freenome, Inc. (FRNM)vs ›	$133.45M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PE RATIO

TTM

Sutro Biopharma, Inc. (STRO)

$139.84M

N/A

Alpha Cognition Inc (ACOG)vs ›

$139.47M

N/A

Immuneering Corporation (IMRX)vs ›

$139.04M

N/A

KORU Medical Systems, Inc. (KRMD)vs ›

$137.80M

N/A

1879.79

1257.96

875.52

Atrium Therapeutics, Inc. (RNA)vs ›

$136.67M

N/A

Nyxoah S.A. (NYXH)vs ›

$143.10M

N/A

Organigram Global Inc. (OGI)vs ›

$136.57M

2.18

9.74

18.49

Protara Therapeutics, Inc. (TARA)vs ›

$143.60M

N/A

NervGen Pharma Corp. Common stock (NGEN)vs ›

$143.84M

N/A

Freenome, Inc. (FRNM)vs ›

$133.45M

N/A

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

PE Ratio: N/A

STRO PE Ratio Metrics

STRO Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics